New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Keros Therapeutics, Inc.
KROS
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

2B

Biotechnology

Next Earning date - 04 Nov 2024

2B

Biotechnology

Next Earning date - 04 Nov 2024

61.25USD
Shape0.16 ( 0.26%)
favorite-chart

Relative Strenght

19
favorite-chart

Volume Buzz

-2%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

16%

Quote Panel

Shape
Updated October 19, 2024
1W 1.24 % 1M 9.77 % 3M 26.11 % 1Y 116.13 %

Key Metrics

Shape
  • Market Cap

    2.30B


  • Shares Outstanding

    37.52M


  • Share in Float

    29.84M


  • Dividende

    0


  • Earning Date

    04 Nov 2024


  • Price Target

    61.25


  • Average Volume

    339896


  • Beta

    1.235


  • Range

    27.02-73.0


  • Industry

    Biotechnology


  • Website

    https://www.kerostx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

8480.55x

P/S Ratio

5.25x

P/B Ratio

0.0

Debt/Equity

-62012.5%

Net Margin

$-5.1

EPS

How KROS compares to sector?

P/E Ratio

Relative Strength

Shape

KROS

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$5M

Shape13982%

2025-Revenue

$5.28

Shape-322%

2025-EPS

$1M

Shape98%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Guggenheim

initialise

Previous: Not converted

2024-09-23

Now: Buy

Oppenheimer

initialise

Previous: Not converted

2024-06-24

Now: Outperform

BTIG

initialise

Previous: Not converted

2022-07-27

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.92
vs -0.87

Q4.22

arrow
arrow

N/A

-1.09
vs -0.30

Q1.23

arrow
arrow

N/A

-1.26
vs -1.01

Q2.23

arrow
arrow

N/A

-1.27
vs -1.13

Q3.23

arrow
arrow

N/A

-1.33
vs -0.92

Q4.23

arrow
arrow

N/A

-1.34
vs -1.09

Q1.24

arrow
arrow

N/A

-1.21
vs -1.26

Q2.24

arrow
arrow

N/A

-1.25
vs -1.27

Q3.24

arrow
arrow

N/A

-1.27
vs -1.33

Q4.24

arrow
arrow

N/A

-1.23
vs -1.34

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

-100%

NA  vs 20M

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

-100%

NA  vs 100K

Q3.23

arrow
arrow

NA

8K  vs NA

Q4.23

arrow
arrow

NA

143K  vs NA

Q1.24

arrow
arrow

NA

83K  vs NA

Q2.24

arrow
arrow

NA

37K  vs NA

Q3.24

arrow
arrow

+289%

31.1K  vs 8K

Q4.24

arrow
arrow

+1807%

2.7M  vs 143K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-8%

-0.08
vs -0.11

Q4.22

arrow
arrow

-11%

-0.11
vs -0.08

Q1.23

arrow
arrow

-9%

-0.09
vs -0.11

Q2.23

arrow
arrow

-11%

-0.11
vs -0.09

Q3.23

arrow
arrow

-13%

-0.13
vs -0.11

Q4.23

arrow
arrow

-12%

-0.12
vs -0.13

Q1.24

arrow
arrow

-9%

-0.09
vs -0.12

Q2.24

arrow
arrow

-11%

-0.11
vs -0.09

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

112

112
vs 102

10%

Q4.22

arrow
arrow

127

127
vs 112

13%

Q1.23

arrow
arrow

131

131
vs 127

3%

Q2.23

arrow
arrow

123

123
vs 131

-6%

Q3.23

arrow
arrow

106

106
vs 123

-14%

Q4.23

arrow
arrow

121

121
vs 106

14%

Q1.24

arrow
arrow

150

150
vs 121

24%

Q2.24

arrow
arrow

152

152
vs 150

1%

Earnings Growth

Latest News